编者按：原发性中枢神经系统（central nervous system，CNS）黑色素瘤非常罕见，每年发病率约为0.01/10万[1,2]，占所有黑色素瘤的1% [3-5]。临床症状和影像学表现缺乏特异性，目前诊断主要依靠组织或细胞病理学活检、免疫组化检测和分子病理学检测。原发性CNS黑色素瘤尚无标准的治疗方案，临床上多采用手术、放射治疗和化学治疗，但疗效并不理想。

本期「专家组稿」由吉林大学第一医院吴荻教授担任执行主编，与吉林大学第一医院肿瘤内科硕士郭鹏娜共同分享原发性CNS黑色素瘤的流行病学、临床病理特征及现有的诊疗方法，并提出了潜在的治疗策略。

专家介绍

吴荻

吉林大学第一医院肿瘤中心博士研究生导师、主任医师

吉林大学第一医院肿瘤综合治疗区主任、教授

中国临床肿瘤学会（CSCO）理事

中国临床肿瘤学会黑色素瘤专家委员会副主任委员

中国临床肿瘤学会小细胞肺癌专家委员会委员

中国临床肿瘤学会骨与软组织肉瘤专家委员会委员

中国抗癌协会肿瘤转移专业委员会委员

中国临床肿瘤学会肿瘤心脏病学专家委员会常务委员

郭鹏娜

吉林大学第一医院肿瘤内科硕士

主要研究方向：黑色素瘤的靶向、免疫、化疗等综合治疗。

题目：原发性中枢神经系统黑色素瘤的临床病理特征、诊治现状及进展

◾ 作者：郭鹏娜

◾ 执行主编：吴荻

一、疾病特点

一项回顾性研究中分析发现原发性CNS黑色素瘤发病年龄存在两个高峰，分别为第1个十年和第4个十年[1,6-9]，占比为16.7%和21.8% [6]。对59名患者进行性别分析发现男女比例为1.46:1[6]。也有一些小样本或个案报道的研究结果与其并不一致[10-15]。主要发病部位以脑膜为主，其次为脑实质和脊柱。颞叶和额叶也是常被报道的发病部位[16]。

大多数原发性CNS黑色素瘤直接由黑色素细胞恶性转化而来，少数与脑膜黑色素细胞瘤有关[7-10,17-23]。临床表现主要取决于肿瘤的解剖位置和受压神经的结构[22]。当肿瘤位于脑部时，多表现为颅内高压、脑积水、局灶性神经功能缺损、蛛网膜下腔出血和癫痫发作[1,6,24,25]。位于脊柱的病变常与背部疼痛、肢体无力、感觉和运动障碍有关[6,26]。

二、影像学表现

MRI是原发性CNS黑色素瘤诊断首选的影像学方法[4]，但影像学表现受黑色素含量的多少以及有无出血的影响[2,14,27]。当黑色素含量＞10%的肿瘤多表现为T1加权图像高信号，T2加权图像低信号，称之为“黑素细胞”模式，反之亦然[2,14,19,23,27-31]。原发性CNS黑色素瘤瘤内出血的顺磁产物高铁血红蛋白、含铁血黄素可以降低T1、T2的弛豫时间，影响原发性CNS黑色素瘤的诊断[10,22,32-35]。

三、诊断和鉴别诊断

根据1976年Hayward提出的标准，原发性CNS黑色素瘤的诊断需具备CNS外或CNS其他部位不存在黑色素瘤，同时组织病理学证实为黑色素瘤[1,10,36-38]。原发性CNS黑色素瘤的临床症状和影像学表现与黑色素瘤脑转移、CNS色素性病变非常相似，仅凭组织细胞病理学及免疫组化检测难以鉴别。当CNS和CNS外共存黑色素瘤或CNS多发黑色素瘤时，明确诊断CNS肿瘤是否原发及原发部位极为困难。

四、治疗

1.传统治疗

早期原发性CNS黑色素瘤首选手术切除，肿瘤的位置和大小决定肿瘤的手术方式[39] 。无法完全切除的肿瘤附加根治性放疗，有利于肿瘤局部控制及改善预后[40,41]。在目前为止样本量最大的回顾性研究中，Carolina等纳入了54例原发性CNS黑色素瘤。7例进行活检（biospy，B），4例接受部分切除（subtotal resection，STR），活检术后和部分切除的患者平均生存期（mean survival）相近，分别为10、9.5个月。22例接受完全切除（gross total resection ，GTR）的患者平均生存期明显提高，可达31个月。其中接受GTR、化疗（chemotherapy，CT）和放疗（radiation therapy，RT）综合治疗的平均生存期为17.5个月，GTR+CT为15个月，而GTR+RT可达34.5个月[42]。结果表明接受GTR的原发性CNS黑色素瘤患者临床获益明显，而无法完成 GTR的患者，采用STR + RT能够显著改善患者预后。然而由于原发性CNS黑色素瘤的罕见性及高级别循证医学证据的缺乏，标准治疗方案尚无法确定。

晚期CNS黑色素瘤的治疗以全身化疗为主。目前为止，文献中尚未发现有充分证据的化疗方案，大多采用替莫唑胺、达卡巴嗪、铂类药物及鞘内注射甲氨蝶呤进行化疗，随访时间在2 -48个月之间，中位无进展生存期（progress free survival，PFS）为5个月，中位总生存期（overall survival，OS）为12.5个月 [1,2,23,43-49]。

2.靶向治疗与免疫治疗

原发性CNS黑色素瘤中只有极少数病例采用靶向治疗和免疫治疗。6例接受靶向治疗的原发性CNS黑色素瘤，所有患者均有不同程度症状、体征改善，中位OS为7.2个月（4.8-9.6个月）。其中1例NRAS突变患者PFS为5个月[50-52]。5例接受免疫治疗的5例原发性CNS黑色素瘤[5,53-56]，中位OS为58个月（5-63个月）。

总结

原发性CNS黑色素瘤发病罕见[1,2]，临床表现和影像学表现不典型，诊断多依靠病理组织活检。目前原发性CNS黑色素瘤尚无标准治疗方案，手术切除是第一治疗选择，术后辅助放疗似乎会带来一些生存获益。靶向治疗和免疫治疗有望成为原发性CNS黑色素瘤潜在的治疗选择，接受多学科综合治疗疗效可能更佳。但目前仍缺乏针对原发性CNS黑色素瘤患者的大样本临床研究。深入研究原发性CNS黑色素瘤发病机制、分子病理学和肿瘤免疫微环境特征，可为未来治疗策略的发展提供理论基础。

参考文献：

1. Hsieh YY, Yang ST, Li WH, Hu CJ, Wang LS. Primary leptomeningeal melanoma mimicking meningitis: a case report and literature review. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Apr 20 2015;33(12):e57-61. doi:10.1200/jco.2013.50.0264

2. Rosenthal G, Gomori JM, Tobias S, Diment J, Shoshan Y. Unusual cases involving the CNS and nasal sinuses: Case 1. Primary leptomeningeal melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Oct 15 2003;21(20):3875-7. doi:10.1200/jco.2003.10.014

3. Byun J, Park ES, Hong SH, et al. Clinical outcomes of primary intracranial malignant melanoma and metastatic intracranial malignant melanoma. Clinical neurology and neurosurgery. Jan 2018;164:32-38. doi:10.1016/j.clineuro.2017.11.012

4. Balakrishnan R, Porag R, Asif DS, Satter AM, Taufiq M, Gaddam SS. Primary Intracranial Melanoma with Early Leptomeningeal Spread: A Case Report and Treatment Options Available. Case reports in oncological medicine. 2015;2015:293802. doi:10.1155/2015/293802

5. El Habnouni C, Bléchet C, Bens G. Pembrolizumab for primary malignant melanoma of the central nervous system. Journal of neuro-oncology. Aug 2018;139(1):225-227. doi:10.1007/s11060-018-2848-y

6. Kiel FW, Starr LB, Hansen JL. Primary melanoma of the spinal cord. Journal of neurosurgery. Sep 1961;18:616-29. doi:10.3171/jns.1961.18.5.0616

7. Nicolaides P, Newton RW, Kelsey A. Primary malignant melanoma of meninges: atypical presentation of subacute meningitis. Pediatric neurology. Feb 1995;12(2):172-4. doi:10.1016/0887-8994(94)00155-u

8. Narayan RK, Rosner MJ, Povlishock JT, Girevendulis A, Becker DP. Primary dural melanoma: a clinical and morphological study. Neurosurgery. Dec 1981;9(6):710-7. doi:10.1227/00006123-198112000-00017

9. Weindling SM, Press GA, Hesselink JR. MR characteristics of a primary melanoma of the quadrigeminal plate. AJNR American journal of neuroradiology. Jan-Feb 1988;9(1):214-5.

10. Mlaiki A, Ksira I, Ladib M, Guesmi H, Krifa H. [Intradural and cervical primary malignant melanoma. Case report and review of the literature]. Neuro-Chirurgie. Mar 2004;50(1):42-6. Le mélanome malin primitif intra-dural et cervical. A propos d'un cas et revue de la littérature. doi:10.1016/s0028-3770(04)98304-x

11. Bergdahl L, Boquist L, Liliequist B, Thulin CA, Tovi D. Primary malignant melanoma of the central nervous system. A report of 10 cases. Acta neurochirurgica. 1972;26(2):139-49. doi:10.1007/bf01406550

12. Helseth A, Helseth E, Unsgaard G. Primary meningeal melanoma. Acta oncologica (Stockholm, Sweden). 1989;28(1):103-4. doi:10.3109/02841868909111189

13. Salpietro FM, Alafaci C, Gervasio O, et al. Primary cervical melanoma with brain metastases. Case report and review of the literature. Journal of neurosurgery. Oct 1998;89(4):659-66. doi:10.3171/jns.1998.89.4.0659

14. Farrokh D, Fransen P, Faverly D. MR findings of a primary intramedullary malignant melanoma: case report and literature review. AJNR American journal of neuroradiology. Nov-Dec 2001;22(10):1864-6.

15. Hajhouji F, Ganau M, Helene C, et al. Rare encounters: Primary pineal malignant melanoma with lepto-meningeal spread. Case report and literature review on management challenges and outcomes. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. Jul 2019;65:161-165. doi:10.1016/j.jocn.2019.03.029

16. Gibson JB, Burrows D, Weir WP. Primary melanoma of the meninges. https://doi.org/10.1002/path.1700740220. The Journal of Pathology and Bacteriology. 1957/10/01 1957;74(2):419-438. doi:https://doi.org/10.1002/path.1700740220

17. Le Douarin NM, Dupin E. The "beginnings" of the neural crest. Developmental biology. Dec 1 2018;444 Suppl 1:S3-s13. doi:10.1016/j.ydbio.2018.07.019

18. Angelino G, De Pasquale MD, De Sio L, et al. NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications. BMC cancer. Jul 20 2016;16:512. doi:10.1186/s12885-016-2556-y

19. Küsters-Vandevelde HV, Küsters B, van Engen-van Grunsven AC, Groenen PJ, Wesseling P, Blokx WA. Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects. Brain pathology (Zurich, Switzerland). Mar 2015;25(2):209-26. doi:10.1111/bpa.12241

20. Schneider SJ, Blacklock JB, Bruner JM. Melanoma arising in a spinal nerve root. Case report. Journal of neurosurgery. Dec 1987;67(6):923-7. doi:10.3171/jns.1987.67.6.0923

21. Urtatiz O, Cook C, Huang JL, Yeh I, Van Raamsdonk CD. GNAQ(Q209L) expression initiated in multipotent neural crest cells drives aggressive melanoma of the central nervous system. Pigment cell & melanoma research. Jan 2020;33(1):96-111. doi:10.1111/pcmr.12843

22. Albano L, Losa M, Barzaghi LR, et al. Primary sellar melanocytoma: pathological, clinical and treatment review. Journal of endocrinological investigation. May 2020;43(5):575-585. doi:10.1007/s40618-019-01158-8

23. Tosaka M, Tamura M, Oriuchi N, et al. Cerebrospinal fluid immunocytochemical analysis and neuroimaging in the diagnosis of primary leptomeningeal melanoma. Case report. Journal of neurosurgery. Mar 2001;94(3):528-32. doi:10.3171/jns.2001.94.3.0528

24. Liubinas SV, Maartens N, Drummond KJ. Primary melanocytic neoplasms of the central nervous system. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. Oct 2010;17(10):1227-32. doi:10.1016/j.jocn.2010.01.017

25. Hauth L, Montagna M, Cras P. Stroke-like symptoms and leptomeningeal FLAIR hyperintensity in a neurofibromatosis type 1 patient with primary leptomeningeal melanoma. Acta neurologica Belgica. Jun 2018;118(2):335-336. doi:10.1007/s13760-018-0931-y

26. Jo KW, Kim SR, Kim SD, Park IS. Primary thoracic epidural melanoma : a case report. Asian Spine J. Jun 2010;4(1):48-51. doi:10.4184/asj.2010.4.1.48

27. Kang SG, Yoo DS, Cho KS, et al. Coexisting intracranial meningeal melanocytoma, dermoid tumor, and Dandy-Walker cyst in a patient with neurocutaneous melanosis. Case report. Journal of neurosurgery. Mar 2006;104(3):444-7. doi:10.3171/jns.2006.104.3.444

28. Roser F, Nakamura M, Brandis A, Hans V, Vorkapic P, Samii M. Transition from meningeal melanocytoma to primary cerebral melanoma. Case report. Journal of neurosurgery. Sep 2004;101(3):528-31. doi:10.3171/jns.2004.101.3.0528

29. Varela-Poblete J, Vidal-Tellez A, Cruz-Quiroga JP, Montoya-Salvadores F, Medina-Escobar J. Melanocytic lesions of the central nervous system: a case series. Arquivos de neuro-psiquiatria. Feb 2022;80(2):153-160. doi:10.1590/0004-282x-anp-2021-0082

30. Navas M, Pascual JM, Fraga J, et al. Intracranial intermediate-grade meningeal melanocytoma with increased cellular proliferative index: an illustrative case associated with a nevus of Ota. Journal of neuro-oncology. Oct 2009;95(1):105-115. doi:10.1007/s11060-009-9907-3

31. Arantes M, Castro AF, Romão H, et al. Primary pineal malignant melanoma: case report and literature review. Clinical neurology and neurosurgery. Jan 2011;113(1):59-64. doi:10.1016/j.clineuro.2010.08.003

32. Saadeh YS, Hollon TC, Fisher-Hubbard A, Savastano LE, McKeever PE, Orringer DA. Primary diffuse leptomeningeal melanomatosis: Description and recommendations. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. Apr 2018;50:139-143. doi:10.1016/j.jocn.2018.01.052

33. Faro SH, Koenigsberg RA, Turtz AR, Croul SE. Melanocytoma of the cavernous sinus: CT and MR findings. AJNR American journal of neuroradiology. Jun-Jul 1996;17(6):1087-90.

34. de la Fouchardière A, Cabaret O, Pètre J, et al. Primary leptomeningeal melanoma is part of the BAP1-related cancer syndrome. Acta neuropathologica. Jun 2015;129(6):921-3. doi:10.1007/s00401-015-1423-2

35. Woodruff WW, Jr., Djang WT, McLendon RE, Heinz ER, Voorhees DR. Intracerebral malignant melanoma: high-field-strength MR imaging. Radiology. Oct 1987;165(1):209-13. doi:10.1148/radiology.165.1.3628773

36. Hayward RD. Malignant melanoma and the central nervous system. A guide forification based on the clinical findings. Journal of neurology, neurosurgery, and psychiatry. Jun 1976;39(6):526-30. doi:10.1136/jnnp.39.6.526

37. Halder A, Bera S, Datta C, Chatterjee U, Choudhuri MK. Squash cytopathology of primary meningeal melanocytoma. Neurology India. Jan-Feb 2016;64(1):152-4. doi:10.4103/0028-3886.173644

38. Vij M, Jaiswal S, Jaiswal AK, Behari S. Primary spinal melanoma of the cervical leptomeninges: report of a case with brief review of literature. Neurology India. Sep-Oct 2010;58(5):781-3. doi:10.4103/0028-3886.72209

39. Rades D, Tatagiba M, Brandis A, Dubben HH, Karstens JH. [The value of radiotherapy in treatment of meningeal melanocytoma]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. Jun 2002;178(6):336-42. Stellenwert der Strahlentherapie bei der Behandlung des meningealen Melanozytoms. doi:10.1007/s00066-002-0930-y

40. Fernandez C, Hoeltzel G, Werner-Wasik M, Kenyon LC, Shi W. Definitive radiotherapy for meningeal brainstem melanocytoma: a case report. British journal of neurosurgery. Dec 26 2020:1-4. doi:10.1080/02688697.2020.1864291

41. Turhan T, Oner K, Yurtseven T, Akalin T, Ovul I. Spinal meningeal melanocytoma. Report of two cases and review of the literature. Journal of neurosurgery. Mar 2004;100(3 Suppl Spine):287-90.

42. Puyana C, Denyer S, Burch T, et al. Primary Malignant Melanoma of the Brain: A Population-Based Study. World neurosurgery. Oct 2019;130:e1091-e1097. doi:10.1016/j.wneu.2019.07.095

43. Pan Z, Yang G, Wang Y, Yuan T, Gao Y, Dong L. Leptomeningeal metastases from a primary central nervous system melanoma: a case report and literature review. World journal of surgical oncology. Aug 20 2014;12:265. doi:10.1186/1477-7819-12-265

44. Martin-Blondel G, Rousseau A, Boch AL, Cacoub P, Sène D. Primary pineal melanoma with leptomeningeal spreading: case report and review of the literature. Clinical neuropathology. Sep-Oct 2009;28(5):387-94.

45. Williams HI. Primary malignant meningeal melanoma associated with benign hairy naevi. The Journal of pathology. Oct 1969;99(2):171-2. doi:10.1002/path.1710990211

46. Bocquillon P, Berteloot AS, Maurage CA, Mackowiak-Cordoliani MA, Pasquier F, Bombois S. [Primitive leptomeningeal malignant melanoma: a rare etiology of pachymeningitis and leptomeningitis]. Revue neurologique. Nov 2010;166(11):927-30. Mélanome malin leptoméningé primitif : une étiologie rare de pachy- et leptoméningite. doi:10.1016/j.neurol.2010.03.011

47. Allcutt D, Michowiz S, Weitzman S, et al. Primary leptomeningeal melanoma: an unusually aggressive tumor in childhood. Neurosurgery. May 1993;32(5):721-9; discussion 729. doi:10.1227/00006123-199305000-00004

48. Salisbury JR, Rose PE. Primary central nervous malignant melanoma in the bathing trunk naevus syndrome. Postgraduate medical journal. Jun 1989;65(764):387-9. doi:10.1136/pgmj.65.764.387

49. Sagiuchi T, Ishii K, Utsuki S, et al. Increased uptake of technetium-99m-hexamethylpropyleneamine oxime related to primary leptomeningeal melanoma. AJNR American journal of neuroradiology. Sep 2002;23(8):1404-6.

50. Schäfer N, Scheffler B, Stuplich M, et al. Vemurafenib for leptomeningeal melanomatosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Apr 10 2013;31(11):e173-4. doi:10.1200/jco.2012.46.5773

51. Hanft KM, Hamed E, Kaiser M, et al. Combinatorial effects of azacitidine and trametinib on NRAS-mutated melanoma. Pediatric blood & cancer. Apr 2022;69(4):e29468. doi:10.1002/pbc.29468

52. Kinsler VA, O'Hare P, Jacques T, Hargrave D, Slater O. MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children. British journal of cancer. Apr 11 2017;116(8):990-993. doi:10.1038/bjc.2017.49

53. Burgos R, Cardona AF, Santoyo N, et al. Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab. Frontiers in oncology. 2021;11:691017. doi:10.3389/fonc.2021.691017

54. Küsters-Vandevelde HV, Kruse V, Van Maerken T, et al. Copy number variation analysis and methylome profiling of a GNAQ-mutant primary meningeal melanocytic tumor and its liver metastasis. Experimental and molecular pathology. Feb 2017;102(1):25-31. doi:10.1016/j.yexmp.2016.12.006

55. Fujimori K, Sakai K, Higashiyama F, Oya F, Maejima T, Miyake T. Primary central nervous system malignant melanoma with leptomeningeal melanomatosis: a case report and review of the literature. Neurosurgical review. Jan 2018;41(1):333-339. doi:10.1007/s10143-017-0914-0

56. Aaroe AE, Glitza Oliva IC, Al-Zubidi N, et al. Pearls & Oy-sters: Primary Pineal Melanoma With Leptomeningeal Carcinomatosis. Neurology. Aug 3 2021;97(5):248-250. doi:10.1212/wnl.0000000000012121

版权声明

本文版权归医悦汇所有。欢迎转发分享，其他任何媒体如需转载或引用本网版权所有内容，须获得授权，且在醒目位置处注明“转自：医悦汇”。